US Patent Issued to Shanghai Longwood Biopharmaceuticals on May 19 for "Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis B" (Chinese Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,564, issued on May 19, was assigned to Shanghai Longwood Biopharmaceuticals Co. Ltd. (Shanghai).

"Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis B" was invented by Zhe Wang (Shanghai), Zhihong Zeng (Shanghai) and Lei Zhang (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to an internal cyclic sulphiamidine amide-aryl amide compound and a use thereof for treating hepatitis B. Specifically, disclosed is a compound that may act as an HBV replication inhibitor and that has a structure represented by chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutica...